Please use this identifier to cite or link to this item:
|Title:||Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions.|
|Authors:||Villemagne, Victor L;Okamura, Nobuyuki|
|Affiliation:||Department of Nuclear Medicine & Centre for PET, Austin Health, Heidelberg, Victoria, Australia|
Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Heidelberg, Victoria, Australia
|Citation:||Current opinion in neurobiology 2016; 36: 43-51|
|Abstract:||In vivo tau imaging allows a deeper understanding of tau deposition in the brain, providing insights into the causes, diagnosis and treatment of primary and secondary tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The cross-sectional and longitudinal assessment of the temporal and spatial patterns of tau deposition in the brain will allow a better understanding of the role tau plays in ageing as well as its relationship with cognition, genotype, and neurodegeneration. It is likely that selective tau imaging could be used as a diagnostic and prognostic biomarker of disease progression, as well as a surrogate marker for monitoring of efficacy and patient recruitment for disease-specific therapeutic trials.|
Research Support, Non-U.S. Gov't
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.